Antibe Therapeutics Inc. (“Antibe” or the “Corporation”) (TSXV:ATE;
OTCQX:ATBPF) is pleased to report the results of the voting on the
matters submitted to the annual meeting of shareholders of the
Corporation held on October 1, 2014.
The matters voted upon at the meeting and the results of the voting were
as follows:
Item 1: Election of Directors
Each of the six nominees proposed by management was elected to serve as
a director of the Corporation and to hold office for the ensuing year or
until a successor is elected or appointed. The directors are:
Walt Macnee
Jonathan Ross Goodman
John Wallace
Dan Legault
Roderick
Flower
Samira Sakhia
Item 2: Appointment of Auditors
Zeifmans LLP, Chartered Accountants, was appointed the auditors of the
Company for the ensuing year at a remuneration to be fixed by the
directors of the Company.
Item 3: Amendment of the Stock Option Plan
On a vote by disinterested shareholders, the amended and restated Stock
Option Plan of the Corporation as described in the management
information circular was approved.
About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s
technology involves linking a hydrogen sulfide-releasing molecule to an
existing drug to produce a patented, improved medicine. Antibe’s ATB-346
targets the global need for safer non-steroidal anti-inflammatory drugs
(NSAIDs).
Neither the TSX Venture Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2014